APAC-Focused Novotech Buys US CRO and Expands Global Footprint

Novotech, an Asia-Pacific contract research organization (CRO) specializing in biotech, has acquired US-based CRO NCGS as part of a push to expand its services for its global base of clients.

The takeover will help Novotech deliver clinical trials in Asia-Pacific for US clients, and provide Asia-Pacific clients with clinical services in the US to support later phase global studies.

Novotech’s Asia-Pacific sites include integrated labs and Phase 1 facilities providing drug development consulting and clinical development services.

The company also has a US site base of hundreds of investigators with relationships spanning nearly four decades.

Thanks to a $760 million funding round in January, Novotech now has the firepower and appetite for M&A deals and data, AI, and tech-enabled offerings. The January round was joined by a number of global investors, new and old, including controlling shareholder TPG Capital, an Asia-focused private equity platform of global alternative asset firm TPG.

NCGS, a CRO Covering Many Bases

Established in South Carolina in 1984, NCGS is a privately held CRO catering to biopharma clients. The company hires about 300 professionals across the US.

NCGS focuses on multiple areas of clinical development ranging from oncology, hematology, infectious diseases, and CNS in both adult and children populations.

Nancy C. G. Snowden, Founder and CEO of NCGS believes the takeover will be smooth.

“We have a similar cultural fit and focus on excellence so joining Novotech will be seamless for our clients and Novotech’s clients,” said Snowden, adding that the two companies had worked together for over ten years.

Author

Joy Lin

Without knowledge, there is no imagination. Without imagination, knowledge is meaningless